$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000144702823000025 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$4.651M	$6.687M
YoY Change	-67.34%	-46.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.980M	$5.552M
YoY Change	15.0%	13.49%
% of Gross Profit
Research & Development	$17.69M	$18.28M
YoY Change	-22.88%	-1.01%
% of Gross Profit
Depreciation & Amortization	$342.0K	$334.0K
YoY Change	-10.7%	-15.23%
% of Gross Profit
Operating Expenses	$23.04M	$24.10M
YoY Change	-18.74%	2.31%
Operating Profit	-$18.39M	-$17.41M
YoY Change	30.31%	58.68%
Interest Expense	$1.291M	$198.0K
YoY Change	167.84%	-60.87%
% of Operating Profit
Other Income/Expense, Net	$1.291M	$1.074M
YoY Change	-1655.42%	-409.51%
Pretax Income	-$17.09M	-$16.34M
YoY Change	20.45%	44.32%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.09M	-$16.34M
YoY Change	20.45%	3.64%
Net Earnings / Revenue	-367.53%	-244.34%
Basic Earnings Per Share	-$0.10	-$0.10
Diluted Earnings Per Share	-$0.10	-$0.10
COMMON SHARES
Basic Shares Outstanding	166.1M shares	162.6M shares
Diluted Shares Outstanding	166.1M shares	161.6M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$152.5M	$146.7M
YoY Change	1.52%	-11.33%
Cash & Equivalents	$27.20M	$40.57M
Short-Term Investments	$125.3M	$106.2M
Other Short-Term Assets	$3.702M	$3.462M
YoY Change	-34.15%	-41.4%
Inventory
Prepaid Expenses
Receivables	$2.614M	$2.664M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$158.8M	$152.9M
YoY Change	0.64%	-11.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.955M	$4.853M
YoY Change	26.62%	-14.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$11.06M	$0.00
YoY Change
Other Assets	$11.00K	$62.00K
YoY Change	-93.89%	-67.37%
Total Long-Term Assets	$18.02M	$38.37M
YoY Change	-68.95%	-40.21%
TOTAL ASSETS
Total Short-Term Assets	$158.8M	$152.9M
Total Long-Term Assets	$18.02M	$38.37M
Total Assets	$176.8M	$191.2M
YoY Change	-18.08%	-19.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.044M	$2.455M
YoY Change		105.61%
Accrued Expenses	$8.158M	$7.644M
YoY Change	-36.52%	-3.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.53M	$25.15M
YoY Change	-17.75%	-22.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$17.60M	$22.16M
YoY Change	-46.45%	-42.64%
Total Long-Term Liabilities	$17.60M	$22.16M
YoY Change	-46.45%	-42.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.53M	$25.15M
Total Long-Term Liabilities	$17.60M	$22.16M
Total Liabilities	$42.13M	$47.31M
YoY Change	-32.8%	-33.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.237B	-$1.220B
YoY Change	6.26%	6.09%
Common Stock	$1.344B	$1.339B
YoY Change	3.53%	3.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$134.7M	$143.9M
YoY Change
Total Liabilities & Shareholders Equity	$176.8M	$191.2M
YoY Change	-18.08%	-19.27%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$17.09M	-$16.34M
YoY Change	20.45%	3.64%
Depreciation, Depletion And Amortization	$342.0K	$334.0K
YoY Change	-10.7%	-15.23%
Cash From Operating Activities	-$19.56M	-$27.30M
YoY Change	-3.62%	-232.41%
INVESTING ACTIVITIES
Capital Expenditures	$859.0K	$117.0K
YoY Change	-505.19%	56.0%
Acquisitions
YoY Change
Other Investing Activities	$2.300M	$16.80M
YoY Change	-116.89%	-128.0%
Cash From Investing Activities	$1.441M	$16.68M
YoY Change	-110.42%	-127.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.742M	$20.42M
YoY Change	4096.46%	77.77%
NET CHANGE
Cash From Operating Activities	-19.56M	-$27.30M
Cash From Investing Activities	1.441M	$16.68M
Cash From Financing Activities	4.742M	$20.42M
Net Change In Cash	-13.38M	$9.798M
YoY Change	-60.67%	-135.05%
FREE CASH FLOW
Cash From Operating Activities	-$19.56M	-$27.30M
Capital Expenditures	$859.0K	$117.0K
Free Cash Flow	-$20.42M	-$27.42M
YoY Change	1.68%	-233.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-34949
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ARBUTUS BIOPHARMA CORP
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
CY2023Q1	dei	City Area Code CityAreaCode	267
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2023Q1	dei	Security12b Title Security12bTitle	Common Shares, without par value
CY2023Q1	dei	Trading Symbol TradingSymbol	ABUS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	166133563	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40574000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30776000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	106154000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	116137000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2664000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1352000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3462000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2874000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	152854000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	151139000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11135000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10801000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4853000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5070000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	31790000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	37363000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1665000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1744000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	62000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	usd
CY2023Q1	us-gaap	Assets Assets	191224000	usd
CY2022Q4	us-gaap	Assets Assets	195419000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9653000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15055000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16456000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	446000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	372000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	25154000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32857000	usd
CY2023Q1	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	9384000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3296000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5999000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7804000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1671000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1815000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	47309000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165132193	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165132193	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157455363	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157455363	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1339453000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1318737000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	74238000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72406000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1220142000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1203803000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49634000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50488000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	143915000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	191224000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195419000	usd
CY2023Q1	us-gaap	Revenues Revenues	6687000	usd
CY2022Q1	us-gaap	Revenues Revenues	12581000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18275000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18462000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5552000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4892000	usd
CY2023Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	273000	usd
CY2022Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	201000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	24100000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	23555000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17413000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10974000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1268000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	159000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	198000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	506000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1074000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-347000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16339000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11321000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16339000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15765000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161643404	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	161643404	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148428326	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148428326	shares
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	854000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-1071000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15485000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16836000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2131000	usd
CY2023Q1	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	19862000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	259000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	296000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	854000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16339000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	143915000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1736000	usd
CY2022Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	21000	usd
CY2022Q1	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	268000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	236000	usd
CY2022Q1	abus	Stock Issued During Period Value New Issues Share Purchase Agreement StockIssuedDuringPeriodValueNewIssuesSharePurchaseAgreement	10973000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1071000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15765000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	165845000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16339000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15765000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	334000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	394000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2131000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1736000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	273000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	201000	usd
CY2023Q1	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	1178000	usd
CY2022Q1	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	1363000	usd
CY2023Q1	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	197000	usd
CY2022Q1	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	506000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	385000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-168000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1312000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	414000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	468000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1507000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6376000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2102000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4104000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	38840000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-74000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-75000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27301000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20619000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20205000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	61981000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	37000000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16678000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60056000	usd
CY2023Q1	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	0	usd
CY2022Q1	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	10973000	usd
CY2023Q1	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	19862000	usd
CY2022Q1	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	268000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	259000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	296000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	236000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20417000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11485000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9798000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27952000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30776000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40574000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81330000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of business and future operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include hepatitis B virus (“HBV”), SARS-CoV-2 and other coronaviruses. To address HBV, the Company is developing an RNA interference (“RNAi”) therapeutic, AB-729, an oral PD-L1 inhibitor, AB-101, and an oral RNA destabilizer, AB-161, to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV infection (“cHBV”) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. AB-729 is currently being evaluated in multiple phase 2 clinical trials. In addition, a Phase 1 clinical trial with AB-161 was recently initiated. The Company also has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2, where the Company has nominated a compound and has begun IND-enabling preclinical studies. In addition, the Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, the Company had an aggregate of $178.5 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of March 31, 2023. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div>
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	178500000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q1	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	1	subsidiary
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15700000	shares
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7800000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	300000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	273000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7804000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	201000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3627000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	47	numberofsegments
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	53	numberofsegments
CY2023Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	600000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	600000	usd
CY2023Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2455000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3520000	usd
CY2023Q1	abus	Accrued Research And Development AccruedResearchAndDevelopment	5134000	usd
CY2022Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	8261000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	580000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	512000	usd
CY2023Q1	abus	Accrued Payroll Current AccruedPayrollCurrent	1478000	usd
CY2022Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3730000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9653000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2023Q1	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	1178000	usd
CY2022Q1	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	1363000	usd
CY2023Q1	abus	Liability From Sale Of Future Royalties Non Cash Interest Expense LiabilityFromSaleOfFutureRoyaltiesNonCashInterestExpense	197000	usd
CY2022Q1	abus	Liability From Sale Of Future Royalties Non Cash Interest Expense LiabilityFromSaleOfFutureRoyaltiesNonCashInterestExpense	506000	usd
CY2023Q1	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	9384000	usd
CY2022Q1	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	15439000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	4100000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18351000	usd
CY2023Q1	abus	Royalty Entitlements RoyaltyEntitlements	2	product
CY2023Q1	us-gaap	Revenues Revenues	6687000	usd
CY2022Q1	us-gaap	Revenues Revenues	12581000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.90
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.81
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1344550	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.90
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2131000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1736000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1344550	shares

Files In Submission

Name	View Source	Status
abus-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abus-20230331_lab.xml	Edgar Link	unprocessable
abus-20230331_pre.xml	Edgar Link	unprocessable
abus-20230331_htm.xml	Edgar Link	completed
abus-20230331_cal.xml	Edgar Link	unprocessable
0001447028-23-000025-index-headers.html	Edgar Link	pending
0001447028-23-000025-index.html	Edgar Link	pending
0001447028-23-000025.txt	Edgar Link	pending
0001447028-23-000025-xbrl.zip	Edgar Link	pending
a2023-q110xqex311.htm	Edgar Link	pending
a2023-q110xqex312.htm	Edgar Link	pending
a2023-q110xqex321.htm	Edgar Link	pending
a2023-q110xqex322.htm	Edgar Link	pending
abus-20230331.htm	Edgar Link	pending
abus-20230331.xsd	Edgar Link	pending
abus-20230331_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2023 Q2 Form 10-Q Financial Statement

#000144702823000025 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2023 Q2 Form 10-Q Financial Statement

#000144702823000025 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus